Grand Pharmaceutical Group Limited (Grand Pharma) has issued the proxy form for its annual general meeting scheduled for 11:00 a.m. on 5 June 2026 at Unit 3302, The Center, 99 Queen’s Road Central, Hong Kong.

Key items on the agenda include:

1. Financial Statements and Dividend • Shareholders will vote on adopting the audited financial statements for the year ended 31 December 2025. • The board is recommending a final dividend of HK$0.169 per share for the same period.

2. Board Composition and Remuneration • Proposed re-elections: – Mr. Zhou Chao as Executive Director. – Mr. Hu Yebi as Independent Non-Executive Director. – Dr. Pei Geng to continue as Independent Non-Executive Director despite serving more than nine years. • The board seeks authority to determine directors’ remuneration.

3. Auditor Appointment • Renewal of HLB Hodgson Impey Cheng Limited as external auditor until the next AGM, with the board authorised to fix the audit fee.

4. Share Issuance and Repurchase Mandates • Ordinary resolutions will grant the board general mandates to issue new shares and repurchase existing shares. • An additional resolution proposes extending the issuance mandate by the number of shares repurchased.

5. Corporate Governance • A special resolution seeks shareholder approval for amendments to the existing bye-laws and adoption of new bye-laws.

Shareholders must submit proxy forms to Computershare Hong Kong Investor Services Limited no later than 48 hours before the meeting to exercise voting rights in absentia.